Patents by Inventor David Witter
David Witter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230372346Abstract: Treatment regimens for exon 20 insertion mutant cancers with (S)—N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide (Compound 1).Type: ApplicationFiled: September 7, 2021Publication date: November 23, 2023Applicant: CULLINAN PEARL CORP.Inventors: Briggs MORRISON, Jon WIGGINTON, David WITTER, Leigh ZAWEL, Myles CLANCY
-
Publication number: 20230005214Abstract: The disclosed technology provides solutions for generating accurate virtual representations of real-world environments. A process of the disclosed technology can include steps for: aggregating a plurality of images, wherein each of the images is associated with a set of geolocation coordinates, extracting a set of image parameters from the plurality of images, wherein the set of image parameters includes a dynamic range value, and providing the set of image parameters to a three-dimensional (3D) modeling platform. In some aspects, the process can further include generating a virtual environment corresponding with the set of geolocation coordinates, wherein the virtual environment is based on the set of image parameters. Systems and machine-readable media are also provided.Type: ApplicationFiled: June 30, 2021Publication date: January 5, 2023Inventors: Benjamin Goldstein, David Witters
-
Publication number: 20220363707Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.Type: ApplicationFiled: August 5, 2019Publication date: November 17, 2022Applicants: Merck Sharp & Dohme Corp., MSD International GmbHInventors: Michelle Machacek, David Witter, Craig Gibeau, Chunhui Huang, Shuhei Kawamura, David L. Sloman, Phieng Siliphaivanh, Ryan Quiroz, Murray Wan, Sebastian Schneider, Charles S. Yeung, Michael H. Reutershan, Timothy J. Henderson, Jean-Laurent Paparin, Houcine Rahali, Jonathan M. E. Hughes, Sulagna Sanyal, Yingchun Ye, David A. Candito, Patrick S. Fier, Steven M. Silverman
-
Publication number: 20210309687Abstract: The present invention provides a compound of formula (I) Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, are PRMT5 inhibitors. Also provided are methods of making compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.Type: ApplicationFiled: August 5, 2019Publication date: October 7, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Michelle Machacek, David Witter, Chunhui Huang, Shuhei Kawamura, Sebastian Schneider, Murray Wan
-
Publication number: 20210277009Abstract: The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.Type: ApplicationFiled: August 5, 2019Publication date: September 9, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: David Witter, Shuhei Kawamura, Michelle Machacek, Ryan Quiroz, Michael H. Reutershan, Sebastian Schneider, Phieng Siliphaivanh, Yingchun Ye, Charles S. Yeung
-
Patent number: 9988397Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).Type: GrantFiled: December 10, 2015Date of Patent: June 5, 2018Assignees: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTDInventors: Phieng Siliphaivanh, David L. Sloman, David Witter, Umar Faruk Mansoor, Joseph Kozlowski, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu, Yimin Qian, Xianhai Huang
-
Patent number: 9884048Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.Type: GrantFiled: December 10, 2015Date of Patent: February 6, 2018Assignee: MERCK SHARP & DOHME CORP.Inventors: Phieng Siliphaivanh, Joey Methot, Kathryn Ann Lipford, Danielle Molinari, David L. Sloman, David Witter, Hua Zhou, Christopher Boyce, Xianhai Huang, Jongwon Lim, David Guerin, Ganesh Babu Karunakaran, Raman Kumar Bakshi, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu
-
Publication number: 20170266167Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 10, 2015Publication date: September 21, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Phieng Siliphaivanh, Joey Methot, Kathryn Ann Lipford, Danielle Molinari, David L. Sloman, David Witter, Hua Zhou, Christopher Boyce, Xianhai Huang, Jongwon Lim, David Guerin, Ganesh Babu Karunakaran, Raman Kumar Bakshi, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu
-
Publication number: 20170267695Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).Type: ApplicationFiled: December 10, 2015Publication date: September 21, 2017Applicants: Merck Sharp & Dohme Corp., MSD R&D (China) Co., Ltd.Inventors: Phieng Siliphaivanh, David L. Sloman, David Witter, Umar Faruk Mansoor, Joseph Kozlowski, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu, Yimin Qian, Xianhai Huang
-
Patent number: 9096598Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.Type: GrantFiled: September 28, 2012Date of Patent: August 4, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: John W. Butcher, David Witter, Christopher Dinsmore, June Kim, John Hendrix, Raksha Archarya, Sean P. Ahearn, Joon Jung, Alexey Rivkin, Philip Jones
-
Patent number: 9023865Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).Type: GrantFiled: October 25, 2012Date of Patent: May 5, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Jongwon Lim, Elizabeth Helen Kelley, Joey L. Methot, Hua Zhou, Alessia Petrocchi, Umar Faruk Mansoor, Christian Fischer, Brendan O'Boyle, David Joseph Guerin, Corey E. Bienstock, Christopher W. Boyce, Matthew H. Daniels, Danielle Falcone, Ronald D. Ferguson, Salem Fevrier, Xianhai Huang, Kathryn Ann Lipford, David L. Sloman, Kevin Wilson, Wei Zhou, David Witter, Milana M. Maletic, Phieng Siliphaivanh
-
Publication number: 20140303142Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.Type: ApplicationFiled: September 28, 2012Publication date: October 9, 2014Inventors: John W. Butcher, David Witter, Christopher Dinsmore, June Kim, John Hendrix, Raksha Acharya, Sean P. Ahearn, Joon Jung, Alexey Rivkin, Philip Jones
-
Publication number: 20140296203Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).Type: ApplicationFiled: October 25, 2012Publication date: October 2, 2014Inventors: Jongwon Lim, Elizabeth Helen Kelley, Joey L. Methot, Hua Zhou, Alessia Petrocchi, Faruk Mansoor, Christian Fischer, Brendan O'Boyle, David Joseph Guerin, Corey E. Bienstock, Christopher W. Boyce, Matthew H. Daniels, Danielle Falcone, Ronald D. Ferguson, Salem Fevrier, Xianhai Huang, Kathryn Ann Lipford, David L. Sloman, Kevin Wilson, Wei Zhou, David Witter, Milana M. Maletic, Phieng Siliphaivanh
-
Publication number: 20130040933Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof. Compounds of formula I are inhibitors of Janus kinases and as such are useful for the treatment of various diseases and conditions mediated by said enzymes, such as rheumatoid arthritis, asthma, COPD, ALS, and the like.Type: ApplicationFiled: April 21, 2011Publication date: February 14, 2013Inventors: Brandon Cash, Christian Fischer, Yudith Garcia, Joon Jung, Jason Katz, June Kim, Alexey Rivkin, Adam Schell, Tony Siu, David Witter, Hua Zhou
-
Patent number: 8168658Abstract: The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.Type: GrantFiled: February 23, 2007Date of Patent: May 1, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Jonathan B. Grimm, Jed L. Hubbs, Thomas Miller, Karin M. Otte, Phieng Siliphaivanh, Matthew G. Stanton, Kevin Wilson, David Witter, Hua Zhou
-
Patent number: 8158825Abstract: The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: GrantFiled: June 21, 2006Date of Patent: April 17, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Jonathan Grimm, Paul Harrington, Richard Heidebrecht, Jr., Thomas Miller, Karin Otte, Phieng Siliphaivanh, David Sloman, Matthew Stanton, Kevin Wilson, David Witter, Solomon Kattar, Paul Tempest
-
Patent number: 7783695Abstract: A computerized method for rendering images includes receiving from a client a render job having an associated job profile, distributing the render job via a communications medium to at least one of a plurality of render servers based at least in part on the job profile, and rendering the render job. The method also includes forwarding the rendered render job to a network storage system for retrieval by the client.Type: GrantFiled: June 30, 2000Date of Patent: August 24, 2010Assignee: Graphics Properties Holdings, Inc.Inventors: D'Arcy M. Tyrrell, III, Anne P. Wagner, David Witters, Richard A. Petersen, David Lease
-
Publication number: 20100160327Abstract: The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: ApplicationFiled: June 21, 2006Publication date: June 24, 2010Inventors: Jonathan Grimm, Paul Harrington, Richard Heidebrecht, JR., Thomas Miller, Karin Otte, Phieng Siliphaivanh, David Sloman, Matthew Stanton, Kevin Wilson, David Witter, Solomon Kattar, Paul Tempest
-
Publication number: 20090192177Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.Type: ApplicationFiled: August 27, 2008Publication date: July 30, 2009Inventors: Arlindo L. Castelhano, Bryan McKibben, Douglas S. Werner, David Witter
-
Patent number: 7504407Abstract: This invention pertains to compounds having the structure: wherein m is 0, 1, 2, or 3; R2 is a substituted or unsubstituted imidazole or pyrazole wherein the point of attachment of R2 to the alkyl chain is not N; R5 is a hydrogen atom or a substituted or unsubstituted alkyl, aryl, or alkylaryl moiety; and R7 is a halogen atom, C1-C4 alkyl, OH, O-alkyl(C1-C4), NH2, or NH-alkyl(C1-C4), which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compound.Type: GrantFiled: November 27, 2002Date of Patent: March 17, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Arlindo L. Castelhano, Bryan McKibben, Douglas S. Werner, David Witter